SOCS2 antisense RNA 1 (non-protein coding) (SOCS2-AS1)

SOCS2 antisense RNA 1 (SOCS2-AS1) is a long non-coding RNA transcribed from the antisense strand of the SOCS2 gene locus. SOCS2-AS1 acts as a tumor suppressor in endometrial and colorectal cancer, where its reduced expression is associated with advanced disease and poor prognosis[1][4]. It is predominantly cytoplasmic and regulates cancer cell proliferation, cell-cycle progression, apoptosis, and metastasis. SOCS2-AS1 achieves these effects by interacting with key proteins (such as AURKA) and by modulating gene expression through mechanisms such as miRNA sponging (miR-1264), which impacts SOCS2 levels and subsequently influences the JAK/STAT signaling pathway[1][2][4]. In androgen-driven prostate cancer contexts, SOCS2-AS1 modulates chromatin cofactor recruitment in concert with the androgen receptor, shaping the epigenetic landscape of target genes[2]. SOCS2-AS1 itself is regarded as a potential therapeutic target and biomarker for specific drug strategies (notably, AURKA-inhibition) in certain cancers[1].

Other names

SOCS2 antisense RNA 1SOCS2-AS1SOCS2 antisense RNA 1 (non-protein coding)

Drugs altering AR (androgen receptor) activity or AURKA (Aurora kinase A) protein stability may indirectly affect SOCS2-AS1 function and associated pathways. SOCS2-AS1 enhances degradation of AURKA through the ubiquitin-proteasome pathway. SOCS2-AS1 regulates SOCS2 by sponging miR-1264, thus affecting downstream JAK/STAT-related signaling.